Table 5. Cardiovascular side effects in ESA group vs Control group.

ESA = Erythropoiesis stimulating agent

Study	Participants with cardiovascular side effects in the ESA group	Total participants in the ESA group	Participants with cardiovascular side effects in the control group	Total participants in the control group	Type of cardiovascular side effects
Aapro - 2008 [13]	29	231	13	231	Pulmonary embolism, Thrombophlebitis, Deep venous thrombosis
Blohmer - 2011 [14]	2	128	3	129	Pulmonary embolism, Deep venous thrombosis
Cabanillas - 2012 [15]	5	55	2	54	Thrombotic events
Engert - 2010 [16]	6	648	5	655	Vascular disorders
Fujisaka - 2011 [17]	6	89	3	92	Hypertension, Pulmonary embolism
Gascon - 2019 [18]	261	1680	115	836	Thromboembolism, Hypertension,  Ischemic heart disease, Cardiac failure
Gupta - 2009 [19]	0	58	0	57	NA
Hernandez - 2009 [20]	42	194	32	192	Arrhythmia, Cardiac failure, Hypertension, Ischemic heart disease, Thromboembolism, Cardiac arrest, Vascular disorders
Hoskin - 2009 [21]	8	151	7	149	Hypertension, Chest pain, Coronary artery disorder, Cardiac arrest, Thromboembolism
Leyland -Jones - 2016 [22]	29	1050	15	1048	Arterial thrombosis/embolism, Venous thrombosis/embolism, Acute coronary syndrome, Pulmonary embolism
Pirker - 2008 [23]	140	301	101	296	Thromboembolism, Arrhythmia, Heart failure, Coronary artery disorder, Thrombosis (arterial and venous), Hypertension
Platzbecker - 2017 [24]	7	98	8	48	Hypertension, Heart failure, Ischemic heart disease, Thromboembolism (venous and arterial)
Pronzato - 2010 [25]	8	107	7	109	Thrombovascular event
Ray-Coquard - 2009 [26]	5	110	4	108	Thrombovascular event
Smith Jr - 2008 [27]	106	517	87	472	Thromboembolic event, Arterial and venous thrombosis/embolism, Arrhythmia, Heart failure, Coronary artery disorders, Hypertension
Tsuboi - 2009 [28]	5	62	4	58	Thrombovascular event, Hypertension
Untch - 2011 [29]	18	318	12	396	Thromboembolism
Total	677	5797	418	4930	-